Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Daily summary: U.S. indices rise as the dollar softens ahead of the Thanksgiving holiday 🗽
SanDisk will join the S&P 500 index📈
US Open: Nasdaq under pressure from Nvidia and AMD 📌Alphabet shares at all-time high
Nvidia shares decline 4% as Meta Platforms shifts to Google AI chips 📉